Literature DB >> 18503008

Short-term regulation of peptide YY secretion by a mixed meal or peritoneal glucose-based dialysate in patients with chronic renal failure.

Miguel Pérez-Fontán1, Fernando Cordido, Ana Rodríguez-Carmona, Manuel Penín, Helena Díaz-Cambre, Andrés López-Muñiz, Susana Sangiao-Alvarellos, Jesús García-Buela.   

Abstract

BACKGROUND: Malnutrition is very prevalent among patients with chronic renal failure. The role of derangements in the gut-brain axis for regulation of appetite in the genesis of anorexia of these patients has not been adequately investigated. Design. Following a randomized, crossover design, we analysed plasma levels of peptide YY (PYY)(1-36) and PYY(3-36) both fasting and after a standardized oral mixed meal or intraperitoneal glucose infusion in 10 stable uraemic patients undergoing peritoneal dialysis and 8 healthy controls, matched for age, gender and body mass index. Main results. Median baseline plasma levels of PYY(1-36) in the different provocation tests oscillated between 406 and 460 pg/mL in patients, as compared with 73 and 100 pg/mL in controls (P < 0.001). Corresponding values for PYY(3-36) oscillated between 235 and 267 pg/mL in patients, versus 56 and 70 pg/mL in controls (P < 0.001). The association of high levels of PYY(3-36) and normal levels of acylated ghrelin (when compared with healthy controls) configurated a markedly pro-anorexigenic pattern in patients. Neither oral intake nor intraperitoneal glucose resulted in significant changes in plasma levels of PYY(1-36) or PYY(3-36) in subjects with renal failure, in contrast with the expected postprandial rise observed in healthy controls (41% for PYY(1-36), P = 0.04 and 32% for PYY(3-36), P = 0.02, median values).
CONCLUSIONS: Baseline plasma levels of PYY(1-36) or PYY(3-36) are markedly elevated in patients with renal failure undergoing peritoneal dialysis. Provocation studies disclose a marked disregulation in the postprandial secretion of these anorexigenic peptides, when compared with healthy controls. These findings may contribute to clarify the complex pathogenesis of anorexia of chronic renal failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18503008     DOI: 10.1093/ndt/gfn297

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Association of plasma des-acyl ghrelin levels with CKD.

Authors:  Rohit K Gupta; Tamil Kuppusamy; James T Patrie; Bruce Gaylinn; Jianhua Liu; Michael O Thorner; Warren K Bolton
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-06       Impact factor: 8.237

2.  Hormonal regulation of energy-protein homeostasis in hemodialysis patients: an anorexigenic profile that may predispose to adverse cardiovascular outcomes.

Authors:  Manish Suneja; Daryl J Murry; John B Stokes; Victoria S Lim
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-10-19       Impact factor: 4.310

3.  Fasting and postprandial plasma ghrelin levels are decreased in patients with liver failure previous to liver transplantation.

Authors:  Maria Teresa Diz-Lois; Jesús Garcia-Buela; Francisco Suarez; Susana Sangiao-Alvarellos; Ovidio Vidal; Fernando Cordido
Journal:  Endocrine       Date:  2009-04-11       Impact factor: 3.633

Review 4.  Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Authors:  Raymond Vanholder; Anneleen Pletinck; Eva Schepers; Griet Glorieux
Journal:  Toxins (Basel)       Date:  2018-01-08       Impact factor: 4.546

5.  Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial Infarction.

Authors:  Elias Haj-Yehia; Robert Werner Mertens; Florian Kahles; Marcia Viviane Rückbeil; Matthias Rau; Julia Moellmann; Moritz Biener; Mohammad Almalla; Jörg Schroeder; Evangelos Giannitsis; Hugo Albert Katus; Nikolaus Marx; Michael Lehrke
Journal:  J Clin Med       Date:  2020-12-06       Impact factor: 4.241

Review 6.  Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options.

Authors:  Mª Luisa Isidro; Fernando Cordido
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.